GE HealthCare will showcase its latest advancements in breast cancer detection and diagnostics at the 2025 Society of Breast Imaging Symposium, highlighting technologies aimed at improving accuracy and patient-centered care.

Key announcements include:

- The Pristina Via mammography system, which offers improved workflows, faster image processing, and low-dose imaging for patients. It enhances both technologist experience and patient comfort, with zero-click acquisition and rapid image cycles.

- GE HealthCare will distribute DeepHealth’s SmartMammo, an AI-powered solution for radiology workflows, now cleared for use in the U.S. It integrates with Pristina and provides features like real-time data rendering and automatic lesion detection, especially effective for dense breast tissue.

- The Invenia ABUS Premium, an FDA-approved breast ultrasound system, is designed to detect cancer in dense breast tissue. It includes AI tools to enhance image quality, scanning speed, and diagnostic confidence.

- SenoBright HD and SerenaBright, FDA-cleared solutions for contrast-enhanced mammography and guided biopsies, help detect lesions more clearly and conduct biopsies in familiar settings using existing mammography equipment.

The company emphasizes its commitment to improving breast cancer screening through a combination of hardware, AI, and streamlined workflows to enhance diagnostic speed, accuracy, and patient outcomes.

You can find more at GE HealthCare’s booth #407 during the event or by visiting their official site. Let me know if you'd like this shortened further or tailored for a specific purpose.